Core Insights - The conference call will focus on the growing colorectal cancer crisis and emerging data from the BOT/BAL immunotherapy program [5] - The discussion will include perspectives from leading clinicians and address systemic regulatory challenges that delay access to life-extending treatments [5] Company Participants - Key executives from Agenus participating in the call include Garo H. Armen (Founder, Executive Chairman & CEO), Jennifer S. Buell (Director and President & CEO of MiNK Therapeutics), Richard M. Goldberg (Chief Development Officer), Stefanie Perna-Nacar (Chief Communications & Government Relations Officer), and Steven J. O'Day (Chief Medical Officer) [1][3] External Participants - The call will feature external thought leaders such as Dr. Nicholas DeVito (Assistant Professor of Medical Oncology, Duke University) and Dr. Chris O'Callaghan (Senior Investigator, Canadian Cancer Trials Group) [4]
Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)